Virtual CME Program
COVID-19 Web Series Part 7: Antiviral Therapies
In the seventh episode of Pri-Med’s weekly web series on COVID-19, faculty will start off a multi-episode spanning discussion on COVID-19 treatment by analyzing recent evidence of antiviral therapies. They will also review the current recommendations regarding their use in patients with COVID-19. Therapies to be discussed in this episode will include:
- Convalescent Plasma
- Camostat Mesilate
- Lopinavir/Ritonavir
- Hydroxychloroquine and Chloroquine
- Remdesivir
Please note that any data, indications, and guidelines presented in this activity are current as of the recording on 05/14/2020 and they are subject to change as new information is published.
CME/CE Information
0 Credits - Not for CME/CE Credit
Release Date: 5/14/2020
Expiration Date: 5/12/2021
Topics
Learning Objectives
- Recognize that currently no drugs have been proven to be safe and effective for the treatment of COVID-19
- Review the various antiviral therapies under investigation for the treatment of COVID-19
- Describe the potential limitations of various antiviral therapies under investigation
Faculty
Ty J. Gluckman, MD, MHA, FACC, FAHA, FASPC
Medical Director, Center for Cardiovascular Analytics, Research, and Data Science (CARDS), Providence Heart Institute, Providence St. Joseph Health
Portland, OR
Charles Vega, MD, FAAFP
Health Sciences Clinical Professor
UC Irvine Department of Family Medicine
Assistant Dean for Culture and Community Education
Executive Director, UC Irvine Program in Medical Education for the Latino Community
UC Irvine School of Medicine
Irvine, CA
Learn More
Supporters and Partners
Supported by
Not Applicable
Education Partner
Not Applicable